Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
PURPOSE: To present the results of a prospective phase II study in esophageal carcinoma. PATIENTS AND METHODS: Patients received single doses of 1.8 Gy up to 27 Gy, then concomitant boost to a total of 50.4 Gy (PTV2 [planning target volume], single dose 1.8 Gy) and 64.8 Gy (PTV1, single dose 1.2 Gy...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2008
|
| _version_ | 1797087235368026112 |
|---|---|
| author | Brunner, T Rupp, A Melzner, W Grabenbauer, G Sauer, R |
| author_facet | Brunner, T Rupp, A Melzner, W Grabenbauer, G Sauer, R |
| author_sort | Brunner, T |
| collection | OXFORD |
| description | PURPOSE: To present the results of a prospective phase II study in esophageal carcinoma. PATIENTS AND METHODS: Patients received single doses of 1.8 Gy up to 27 Gy, then concomitant boost to a total of 50.4 Gy (PTV2 [planning target volume], single dose 1.8 Gy) and 64.8 Gy (PTV1, single dose 1.2 Gy in the morning and 1.8 Gy in the afternoon) concurrently with 800 mg/m(2)/d 5-fluorouracil and 20 mg/m(2)/d cisplatin (weeks 1 and 5). High-dose-rate brachytherapy (2-3 x 6 Gy) on Fridays of weeks 4-6 used a customized applicator facilitating central placement and circumferential dose homogeneity. RESULTS: 50 patients with squamous cell carcinoma (90%) or adenocarcinoma and mostly advanced tumor stage were treated (82% T3/T4 and 70% N1). Median overall survival (median OS 16 months; 1-year-OS 61%; 2-year OS 29%) was significantly longer for patients without nodal disease (35 vs. 11 months; p = 0.01). Hematotoxicity was grade 3 in 11/50, and grade 4 in 1/50 patients. Four percent of higher-grade nausea or vomiting occurred. Esophageal late toxicity was grade 3 in 9/50 patients, and grade 4 in 2/50 patients. CONCLUSION: Survival was excellent especially for patients without nodal disease in this dose-intensified schedule with acceptable tolerability. |
| first_indexed | 2024-03-07T02:32:55Z |
| format | Journal article |
| id | oxford-uuid:a7d9aa67-9922-4a76-958a-e324a29a49ae |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:32:55Z |
| publishDate | 2008 |
| record_format | dspace |
| spelling | oxford-uuid:a7d9aa67-9922-4a76-958a-e324a29a49ae2022-03-27T02:57:16ZEsophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a7d9aa67-9922-4a76-958a-e324a29a49aeEnglishSymplectic Elements at Oxford2008Brunner, TRupp, AMelzner, WGrabenbauer, GSauer, R PURPOSE: To present the results of a prospective phase II study in esophageal carcinoma. PATIENTS AND METHODS: Patients received single doses of 1.8 Gy up to 27 Gy, then concomitant boost to a total of 50.4 Gy (PTV2 [planning target volume], single dose 1.8 Gy) and 64.8 Gy (PTV1, single dose 1.2 Gy in the morning and 1.8 Gy in the afternoon) concurrently with 800 mg/m(2)/d 5-fluorouracil and 20 mg/m(2)/d cisplatin (weeks 1 and 5). High-dose-rate brachytherapy (2-3 x 6 Gy) on Fridays of weeks 4-6 used a customized applicator facilitating central placement and circumferential dose homogeneity. RESULTS: 50 patients with squamous cell carcinoma (90%) or adenocarcinoma and mostly advanced tumor stage were treated (82% T3/T4 and 70% N1). Median overall survival (median OS 16 months; 1-year-OS 61%; 2-year OS 29%) was significantly longer for patients without nodal disease (35 vs. 11 months; p = 0.01). Hematotoxicity was grade 3 in 11/50, and grade 4 in 1/50 patients. Four percent of higher-grade nausea or vomiting occurred. Esophageal late toxicity was grade 3 in 9/50 patients, and grade 4 in 2/50 patients. CONCLUSION: Survival was excellent especially for patients without nodal disease in this dose-intensified schedule with acceptable tolerability. |
| spellingShingle | Brunner, T Rupp, A Melzner, W Grabenbauer, G Sauer, R Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. |
| title | Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. |
| title_full | Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. |
| title_fullStr | Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. |
| title_full_unstemmed | Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. |
| title_short | Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. |
| title_sort | esophageal cancer a prospective phase ii study of concomitant boost external beam chemoradiation with a top up endoluminal boost |
| work_keys_str_mv | AT brunnert esophagealcanceraprospectivephaseiistudyofconcomitantboostexternalbeamchemoradiationwithatopupendoluminalboost AT ruppa esophagealcanceraprospectivephaseiistudyofconcomitantboostexternalbeamchemoradiationwithatopupendoluminalboost AT melznerw esophagealcanceraprospectivephaseiistudyofconcomitantboostexternalbeamchemoradiationwithatopupendoluminalboost AT grabenbauerg esophagealcanceraprospectivephaseiistudyofconcomitantboostexternalbeamchemoradiationwithatopupendoluminalboost AT sauerr esophagealcanceraprospectivephaseiistudyofconcomitantboostexternalbeamchemoradiationwithatopupendoluminalboost |